Combining the treatment for the most deadly form of skin cancer with a common anti-rheumatic drug could provide more effective results, new research has shown. The findings showed that using "leflunomide" -- an immunosuppressive drug approved for treatment of rheumatoid arthritis -- in combination with another melanoma drug, selumetinib almost completely stopped the growth of a melanoma tumour in mice.